All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Results from a phase II trial on the combined use of rituximab and chemotherapy for the treatment of primary central nervous system lymphoma (PCNSL), were published online in the Oncotarget journal in an article by Lode J Swinnen, Johns Hopkins University, Baltimore, MD, and colleagues from the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) cancer research group.
PCNSL is a rare aggressive non-Hodgkin lymphomas (NHL), typically of B-cell nature. If left untreated, PCNSL patients have a median survival between 1–3 months. Despite high response rates, radiotherapy alone leads to short survival rates, due to disease relapse. Although the addition of the traditional chemotherapy combination (CHOP) does not improve survival, results from phase II studies (DeAngelis et al. 1992, 2002; RTOG/SWOG-9310) have confirmed that pharmaceutical agents able to cross the blood–brain barrier (BBB), like high-dose methotrexate (HD-MTX), significantly prolong PCNSL patients’ survival, with or without radiotherapy. Nevertheless, late neurological toxicity remains a critical issue for such combination treatments.
In this prospective ECOG-ACRIN phase II multicenter trial (E1F05; NCT00335140), the toxicity and efficacy of rituximab and chemotherapy combination treatment – without radiation.– was investigated, as a potentially safer alternative PCNSL regimen. Although rituximab cannot cross the intact BBB, it has been detected in cerebrospinal fluid (CSF; Rubenstein et al., 2003) and rituximab monotherapy has demonstrated remission sustainability in PCNSL patients (Batchelor et al., 2011). The primary endpoints of this study were response rates (overall response rate [ORR] and complete response [CR]) and toxicity. Secondary endpoints included overall survival (OS) and progression-free survival (PFS).
The results of this phase II trial demonstrated the potential use of rituximab and conventional chemotherapy, as a treatment modality for PCNSL. Main limitations included the single-arm design of the study, along with the lack of long-term follow-up neuropsychological and comparative data, to address late treatment safety. According to the authors, the outcomes of this trial are comparable to those seen in HD-MTX and radiotherapy combination studies (SWOG/RTOG-93-10) but without neurotoxicological AEs, and thus they recommend the combined use of rituximab and chemotherapy as a potentially safer PCNSL regimen.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox